Stocks · Health care · Pharmaceutical Preparations

Alkermes plc.

ALKS Clue Score59
Ireland Fiscal year ends December CIK 0001520262 Results filed 3 Nov 2026

What the insiders did Mostly scheduled

By person

31 insiders · 294 transactions
50.8×

Richard F. Pops holds 50.8 times base salary in stock. $63.61M of shares against $1.25M in salary for 2025.

Salary from the company's own proxy. The shares are what Richard F. Pops last reported holding, valued at $46.17, the price Ordinary Shares was last bought or sold at on the open market here, on 3 Nov 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Richard F Pops
Director and CEO, Alkermes plc
—
$62.69M (47) scheduled
−$62.69M
1,377,740
0.8212%
$63.61M
+126.2%
Craig C. Hopkinson
EVP R&D, Chief Medical Officer
—
$24.75M (30) scheduled
−$24.75M
65,389
0.0390%
$3.02M
—
Michael J Landine
SVP, Corp Dev., Alkermes, Inc.
—
$14.45M (30) scheduled
−$14.45M
281,730
0.1679%
$13.01M
+81.0%
Shane Cooke
Director
—
$12.24M (24) scheduled
−$12.24M
106,679
0.0636%
$4.93M
+66.8%
James M Frates
SVP, Alks Inc; CFO ALKS
—
$7.08M (11) scheduled
−$7.08M
91,828
0.0547%
$4.24M
+262.0%
Elliot Ehrich
EVP, R&D & CMO, Alkermes, Inc.
—
$4.28M (13) scheduled
−$4.28M
57,056
0.0340%
$2.63M
+19.0%
Kathryn L Biberstein
EVP/CAO/CCO/CRO Alks Inc;
—
$3.20M (11) scheduled
−$3.20M
40,200
0.0240%
$1.86M
—
Iain Michael Brown
SVP, Chief Financial Officer
—
$2.58M (5) scheduled
−$2.58M
148,196
0.0883%
$6.84M
+726.8%
Blair Curtis Jackson
President & CEO, Alkermes plc
—
$2.25M (2) scheduled
−$2.25M
241,308
0.1438%
$11.14M
+312.3%
nancy lynn MD snyderman
Director
$10.00K (1)
$2.24M (1) scheduled
−$2.23M
15,395
0.0092%
$710.79K
—
Christian Todd Nichols
SVP, Chief Commercial Officer
—
$2.20M (9) scheduled
−$2.20M
102,193
0.0609%
$4.72M
—
David Joseph Gaffin
EVP, CLO, Alkermes, Inc.
—
$2.19M (17) scheduled
−$2.19M
219,353
0.1308%
$10.13M
+919.6%
Mark Stejbach
SVP/Chief Comm Off, Alks Inc
—
$1.97M (6) scheduled
−$1.97M
51,065
0.0304%
$2.36M
+70.1%
Paul J Mitchell
Director
—
$1.95M (29) scheduled
−$1.95M
18,174
0.0108%
$839.09K
+127.2%
Robert A Breyer
Director
—
$1.68M (3)
−$1.68M
10,330
0.0062%
$476.94K
−70.6%
Gordon G Pugh
SVP, COO & CRO, Alkermes, Inc.
—
$1.24M (2) scheduled
−$1.24M
59,324
0.0354%
$2.74M
−13.2%
David W Anstice
Director
—
$1.22M (6) scheduled
−$1.22M
84,905
0.0506%
$3.92M
+466.0%
Samuel Joseph Parisi
VP, Finance (Interim PAO)
—
$1.21M (6) scheduled
−$1.21M
7,717
0.0046%
$356.29K
+97.9%
Wendy L Dixon
Director
—
$1.13M (2) scheduled
−$1.13M
53,124
0.0317%
$2.45M
+3,220%
Nancy Wysenski
Director
$278.71K (3)
$1.29M (1) scheduled
−$1.01M
31,598
0.0188%
$1.46M
—
Floyd E Bloom
Director
—
$879.02K (1)
−$879.02K
127,923
0.0763%
$5.91M
0.0%
David Angelo Daglio Jr.
Director
$815.73K (1)
—
+$815.73K
107,780
0.0642%
$4.98M
+139.5%
Cato T Laurencin
Director
—
$343.61K (4) scheduled
−$343.61K
33,769
0.0201%
$1.56M
—
Brian P McKeon
Director
$264.27K (1)
—
+$264.27K
48,536
0.0289%
$2.24M
—
Christopher I Wright
Director
—
$90.20K (1) scheduled
−$90.20K
25,680
0.0153%
$1.19M
—
Emily Peterson Alva
Director
$49.86K (1)
—
+$49.86K
27,302
0.0163%
$1.26M
—
Frank Anders Wilson
Director
—
—
—
35,751
0.0213%
$1.65M
—
Richard Gaynor
Director
—
—
—
35,751
0.0213%
$1.65M
—
Nancy Lurker
Director
—
—
—
18,222
0.0109%
$841.31K
—
Joshua Reed
SVP, Chief Financial Officer
—
—
—
5,095
0.0030%
$235.24K
—
James A. Robinson Jr.
President & COO,Alkermes, Inc.
—
—
—
4,412
0.0026%
$203.70K
—